[1] Summerskill WH, Walshe JM. Benign recurrent intrahepatic "obstructive" jaundice. Lancet, 1959, 2(7105): 686-690. [2] Summerskill WH. The syndrome of benign recurrant cholestasis. Am J Med, 1965, 38: 298-305. [3] Brenard R, Geubel AP, Benhamou JP. Benign recurrent intrahepatic cholestasis. A report of 26 cases. J Clin Gastroenterol, 1989, 11(5): 546-551. [4] Bijleveld CM, Vonk RJ, Kuipers F, et al. Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients. Hepatology, 1989, 9(4): 532-537. [5] Lachaux A, Loras-Duclaux I, Bouvier R, et al. Benign recurrent cholestasis with normal gamma-glutamyl-transpeptidase activity. J Pediatr, 1992, 121(1): 78-80. [6] De Pagter AG, Van Berge Henegouwen GP, Ten Bokkel Huinink JA, et al. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology, 1976, 71(2): 202-207. [7] Van Mil SW, Van Der Woerd WL, Van Der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology, 2004, 127(2): 379-384. [8] Van Der Woerd WL, Van Mil SW, Stapelbroek JM, et al. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol, 2010, 24(5): 541-553. [9] Klomp LW, Vargas JC, Van Mil SW, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology, 2004, 40(1): 27-38. [10] Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis, 2004, 8(1): 133-149. [11] Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet,, 99(4): 877-885. [12] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consens2016us recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015, 17(5): 405-424. [13] van Ooteghem NA, Klomp LW, Van Berge-Henegouwen GP, et al. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol, 2002, 36(3): 439-443. [14] Halawi A, Ibrahim N, Bitar R. Triggers of benign recurrent intrahepatic cholestasis and its pathophysiology: a review of literature. Acta Gastroenterol Belg, 2021, 84(3): 477-486. [15] Egawa H, Yorifuji T, Sumazaki R, et al. Intractable diarrhea after liver transplantation for Byler's disease: successful treatment with bile adsorptive resin. Liver Transpl, 2002, 8(8): 714-716. [16] Huynh MT, Nguyen TT, Grison S, et al. Clinical characteristics and genetic profiles of young and adult patients with cholestatic liver disease. Rev Esp Enferm Dig, 2019, 111(10): 775-788. [17] Groen A, Romero MR, Kunne C, et al. Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology, 2011, 141(5): 1927-1937.e1921-1924. [18] Verhulst PM, Van Der Velden LM, Oorschot V, et al. A flippase-independent function of ATP8B1, the protein affected in familial intrahepatic cholestasis type 1, is required for apical protein expression and microvillus formation in polarized epithelial cells. Hepatology, 2010, 51(6): 2049-2060. [19] Van Der Mark VA, De Waart DR, Ho-Mok KS, et al. The lipid flippase heterodimer ATP8B1-CDC50A is essential for surface expression of the apical sodium-dependent bile acid transporter (SLC10A2/ASBT) in intestinal Caco-2 cells. Biochim Biophys Acta, 2014, 1842(12 Pt A): 2378-2386. [20] Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis, 2010, 30(2): 125-133. |